sábado, 20 de febrero de 2016

Tuberculosis Caused by Mycobacterium africanum, United States, 2004–2013 - Volume 22, Number 3—March 2016 - Emerging Infectious Disease journal - CDC

Tuberculosis Caused by Mycobacterium africanum, United States, 2004–2013 - Volume 22, Number 3—March 2016 - Emerging Infectious Disease journal - CDC





Volume 22, Number 3—March 2016

CME ACTIVITY - Synopsis

Tuberculosis Caused by Mycobacterium africanum, United States, 2004–2013

Figures

Tables

Technical Appendicies

Downloads

Aditya SharmaComments to Author , Emily Bloss, Charles M. Heilig, and Eleanor S. Click
Author affiliations: Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Abstract

Mycobacterium africanum is endemic to West Africa and causes tuberculosis (TB). We reviewed reported cases of TB in the United States during 2004–2013 that had lineage assigned by genotype (spoligotype and mycobacterial interspersed repetitive unit variable number tandem repeats). M. africanum caused 315 (0.4%) of 73,290 TB cases with lineage assigned by genotype. TB caused by M. africanum was associated more with persons from West Africa (adjusted odds ratio [aOR] 253.8, 95% CI 59.9–1,076.1) and US-born black persons (aOR 5.7, 95% CI 1.2–25.9) than with US-born white persons. TB caused by M. africanum did not show differences in clinical characteristics when compared with TB caused by M. tuberculosis. Clustered cases defined as >2 cases in a county with identical 24-locus mycobacterial interspersed repetitive unit genotypes, were less likely for M. africanum (aOR 0.1, 95% CI 0.1–0.4), which suggests that M. africanum is not commonly transmitted in the United States.
Tuberculosis (TB) is an infectious disease caused by a group of highly-related organisms comprising theMycobacterium tuberculosis complex (MTBC), which includes M. tuberculosis, M. africanum, and M. bovis. Although all members of MTBC might cause disease in humans, M. tuberculosis and M. africanum are the primary cause of disease in humans globally, whereas M. bovis primarily causes disease in cattle (1,2). Like M. tuberculosis, M. africanum is spread by aerosol transmission (3).
Phylogenetic analysis has suggested there are 7 major lineages of MTBC, designated L1–L7 (4,5). M africanumwas traditionally identified by using biochemical methods. However, molecular methods have shown that M. africanum is composed of 2 distinct lineages: L5 (also known in other nomenclature systems as M. africanumWest African 1 [MAF1], West African lineage I), which is genetically part of M. tuberculosis sensu stricto, and L6 (also known as M. africanum West African 2 [MAF2], West African lineage II), which is genetically more similar toM. bovis (4–9).
Among lineages that primarily infect humans, M. africanum lineages are considered phylogenetically more ancient relative to the modern lineages of M. tuberculosis (Euro-American, East African Indian, East Asian). M. africanum has been described as endemic to equatorial Africa, with specimens isolated from countries such as Nigeria, Côte d’Ivoire, Benin, Senegal, Cameroon, Burkina Faso, The Gambia, Sierra Leone, and Uganda (8,10–21). M. africanum has also been isolated from patients with TB in countries in Europe (22–25), Brazil (26), and the United States (27). It is likely that TB caused by M. africanum in non-African countries is secondary to human migration from disease-endemic areas in equatorial Africa (25).
Several studies have explored whether there are clinical differences between TB caused by M. africanum and TB caused by M. tuberculosis. These studies demonstrated variable findings with regard to associations of M. africanum with HIV status and findings on chest radiography (8,28–30). Contacts of persons with TB caused by M. africanum appeared to have a lower rate of progression to active TB compared with contacts of persons with TB caused byM. tuberculosis, and a lower rate of genotype clustering has been described for M. africanum than for M. tuberculosis in relatively small studies from West Africa (14,29).
Although bacterial strains causing TB from all over the world can be found among cases of TB in the United States, analysis of routinely collected genotyping data for 2005–2009 showed that 179 (0.5%) of 36,458 TB cases reported nationally were caused by M. africanum (31). We sought to further expand knowledge of M. africanum in the United States by reviewing all cases of TB reported nationally during 2004–2013. The objectives of this study were to ascertain the proportion of TB cases caused by M. africanum in the United States; compare clinical and epidemiologic characteristics between M. africanum and M. tuberculosis; and determine the extent to which M. africanum strains in the United States might be related by transmission on the basis of genotype clustering.

Methods

Genotype data from the Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) National TB Genotyping Service for 2004 through 2013 were linked to routine demographic and clinical data from all culture-confirmed cases in the CDC National TB Surveillance System from all 50 US states and the District of Columbia (32). As described previously (33), phylogenetic lineage (M. africanum and M. tuberculosis) for TB cases was assigned on the basis of spoligotype by using a set of rules correlating spoligotype to lineages defined by large sequence polymorphisms; for cases that did not meet a full rule for assignment on the basis of spoligotype, 12-locus mycobacterial interspersed repetitive unit variable number tandem repeats (MIRU-VNTRs) was used in addition to spoligotype to assign lineage. Cases reported during 2004–2008 only had 12-locus MIRU-VNTR data available, and cases reported during 2009–2013 had 24-locus MIRU-VNTR data available. To identify cases that could be caused by ongoing transmission in the United States, clusters of cases were defined as >2 cases with the same spoligotype and 24-locus MIRU-VNTR pattern in a given county. Cases that were caused by organisms other than M. africanum or M. tuberculosis were excluded from analysis.
All analyses were conducted by using R statistical software version 3.0.1 (R Core Group, Vienna, Austria). Statistical test results were considered significant at p<0.05. We examined patient attributes, genotype clustering, clinical characteristics (e.g., disease site), and social risk factors (e.g., homelessness) associated with M. africanum and M. tuberculosis. Odd ratios (ORs) and 95% CIs were calculated. Differences in proportions of cases were detected by using Fisher exact and Pearson χ2 tests.
Factors identified as statistically significant by bivariable analysis at p<0.05 were entered into a multivariable logistic regression model to assess whether these factors were independently associated with M. africanum and M. tuberculosis. Tolerance <0.10 was used to detect co-linearity, and the likelihood ratio test was used to test for interaction. To address collinearity between race/ethnicity and origin of birth, variables for race/ethnicity, country of origin, and West African origin were combined into a single variable and included in selection of the multivariable regression model. West African origin was defined as having been born in any of the following countries in West Africa: Nigeria, Liberia, Sierra Leone, Guinea, The Gambia, Ghana, Mali, Senegal, Côte d’Ivoire, Togo, Cameroon, Mauritania, Niger, and Guinea-Bissau.
Ethics Statement
Data for this study were collected as part of routine TB surveillance by CDC. Thus, this study was not considered research involving human subjects, and institutional review board approval was not required.

Results

Thumbnail of Selection of cases included in analysis of tuberculosis (TB) caused by Mycobacterium africanum, United States, 2004–2013.
Figure 1. Selection of cases included in analysis of tuberculosis (TB) caused byMycobacterium africanum, United States, 2004–2013.
A total of 125,038 cases were reported to the National TB Surveillance System during 2004–2013 (Figure 1). Of these cases, 95,836 (76.6%) had a culture result positive for MTBC. Of cases with positive culture results, 73,290 (76.5%) had available lineage identification on the basis of genotype data. Of the cases for which lineage identification was available, the causative agent was determined to be M. africanum for 315 (0.4%) and M. tuberculosis for 71,727 (97.9%) cases: 1,248 (1.7%) cases had an isolated organism other than M. africanum or M. tuberculosis and were excluded from further analysis (Figure 1).
M. africanum was assigned as the causative agent of TB for isolates with a genotype-assigned lineage of L5 or L6. All isolates designated as M. africanum met the conventional spoligotype rule of the absence of spacers 8, 9, and 39 or the absence of spacers 7–9 and 39 (7). M. tuberculosis was assigned as the causative agent of TB for isolates with a genotype-assigned lineage of L1, L2, L3, L4, or L7.
Of the 315 case-patients with TB caused by M. africanum, 155 (49.2%) had the L5 lineage and 160 (50.8%) had the L6 lineage. Case-patients with the L5 lineage were most commonly born in Nigeria (n = 76), Liberia (n = 12), and Ghana (n = 12), and case-patients with the L6 lineage were most commonly born in Liberia (n = 27), Sierra Leone (n = 22), Guinea (n = 17), and The Gambia (n = 16).
Among case-patients with M. africanum as the causative agent of TB, 276 (87.6%) had country of birth other than the United States (Technical Appendix[PDF - 287 KB - 7 pages] Table 1). Of the 276 foreign-born persons with M. africanum, most (254, 92.0%) persons were born in countries in West Africa, such as Nigeria (79, 31.1%), Liberia (39, 15.4%), and Sierra Leone (24, 9.4%).
Thumbnail of Counties in the United States with Mycobacterium africanum infections identified among tuberculosis (TB) cases (black) reported during 2004–2013.
Figure 2. Counties in the United States with Mycobacterium africanum infections identified among tuberculosis (TB) cases (black) reported during 2004–2013.
Among all US states, 35 reported >1 case of TB caused by M. africanum (Figure 2). States that reported more than >10 cases of M. africanum TB during the study were New York (n = 77), Maryland (n = 41), Texas (n = 26), Virginia (n = 19), Georgia (n = 15), and California (n = 14). Across the United States, many reported cases of M. africanum TB appeared to be near major metropolitan areas, such as Atlanta, Georgia; Chicago, Illinois; Detroit, Michigan; Houston, Texas; Los Angeles, California; New York, New York; and Washington, DC.
Thumbnail of A) Annual number of reported Mycobacterium africanum tuberculosis cases and B) corresponding percentage of national genotype surveillance coverage, United States, 2004–2013.
Figure 3. A) Annual number of reported Mycobacterium africanum tuberculosis cases and B) corresponding percentage of national genotype surveillance coverage, United States, 2004–2013.
The annual number of reported TB cases identified with M. africanum in the United States during 2004–2013 ranged from 18 to 40 (median 34 annual cases) (Figure 3). During this period, the proportion of Mycobacteriumspp. TB isolates from persons born in West Africa with culture-confirmed TB that were genotyped ranged from 68.0% to 97.1%, which was comparable with the overall proportion of culture-confirmed TB cases that were genotyped nationally.
On the basis of the genotype cluster definition of >2 cases in the same county with identical spoligotype and 24-locus MIRU-VNTR patterns, only 1 cluster of M. africanum cases was identified during 2009–2013. The cluster consisted of 2 case-patients with the L5 lineage: 1 foreign-born person and 1 US-born person.
Among 315 cases of M. africanum TB, 183 distinct genotypes were identified (spoligotype and 12-locus MIRU-VNTR available for cases reported during 2004–2013; Technical Appendix[PDF - 287 KB - 7 pages] Table 2). Of these 183 genotypes, 139 (76.0%) were found in a single case only; the remaining 44 (24.0%) caused 176 cases. Among 141 M. africanum cases reported during 2009–2013 with spoligotype and 24-locus MIRU-VNTR data available, 123 distinct genotypes were identified (Technical Appendix[PDF - 287 KB - 7 pages] Table 3). Of these 123 genotypes, 113 (91.9%) were found in isolates from 1 case only, and 10 (8.1%) were found in >1 case.
Bivariable analysis showed that M. africanum and M. tuberculosis TB cases had major differences for several characteristics (Technical Appendix[PDF - 287 KB - 7 pages] Table 1). When compared with M. tuberculosis TB cases, M. africanum TB cases had higher odds of being in foreign-born persons (odds ratio [OR] 4.8, 95% CI 3.4–6.7), being in non-Hispanic black or multiracial non-Hispanic persons (OR 27.0, 95% CI 17.1–42.5), originating from countries in West Africa (OR 318.4, 95% CI 239.0–424.2), being in persons positive for HIV (OR 2.8, 95% CI 2.0–3.7), and being in persons with only extrapulmonary disease (OR 1.8, 95% CI 1.4–2.4) or in persons with pulmonary and extrapulmonary disease (OR 1.6, 95% CI 1.1–2.2).
M. africanum TB cases had lower odds than M. tuberculosis TB cases of being in a cluster (defined by spoligotype and 24-locus MIRU) of cases (OR 0.1, 95% CI 0.1–0.2), being in persons >65 years of age (OR 0.2, 95% CI 0.1–0.5), being in persons with an abnormal chest radiographic result and cavitation (OR 0.6, 95% CI 0.5–0.9) and in persons without cavitation (OR 0.5, 95% CI 0.4–0.7), being in a resident of a correctional facility (OR 0.2, 95% CI 0.0–0.6), being in a homeless person (OR 0.4, 95% CI 0.2–0.8), being in persons reporting excessive drug (OR 0.2, 95% CI 0.1–0.5) or alcohol use (OR 0.2, 95% CI 0.1–0.4), and being in persons who died during treatment (OR 0.3, 95% CI 0.2–0.7). Among foreign-born persons, M. africanum TB cases had lower odds than M. tuberculosis TB cases of being in persons who had been in the United States for >5 years before reporting TB (OR 0.3, 95% CI 0.3–0.5).
Multivariable analysis restricted to cases reported during 2009–2013 that had 24-locus MIRU-VNTR data available showed that foreign-born West African origin (OR 253.8, 95% CI 59.9–1076.1) and US-born non−Hispanic black race (OR 5.7, 95% CI 1.2–25.9) were independently associated with TB caused by M. africanum but not with TB caused by M. tuberculosis (Table). Clustered cases (OR 0.1, 95% CI 0.1–0.4) had lower adjusted odds of TB caused by M. africanum than TB caused by M. tuberculosis. Other risk factors were not independently associated with M. africanum versus M. tuberculosis. No significant interaction terms were identified.
To control for possible host differences in larger analysis, we conducted a subanalysis of cases among foreign-born persons from West Africa. In this subanalysis, clustering was the only significant variable at the bivariable level, and M. africanum TB cases had lower odds of being in a cluster of cases thanM. tuberculosis TB cases (OR 0.1, 95% CI 0.1–0.9). Among foreign-born persons with West African origin, we found no significant differences in clinical characteristics (e.g., HIV status, cavitary disease, sputum smear results) between TB cases caused by M. africanum versus those caused by M. tuberculosis.M. africanum TB cases with L5 and L6 lineages had similar proportions of HIV positivity (18.1% vs. 17.5%; p = 0.9) and cavitary disease by chest radiography (25.4% vs. 42.5%; p = 0.051). We found no significant differences in clinical characteristics or social risk factors for TB caused by L5 or L6 lineages.

Discussion

This study used nationally reported data on TB cases linked to genotype data to describe the epidemiology of M. africanum in the United States. The findings from this analysis indicate that M. africanum is a rare cause of TB in the United States and represents 315 (0.4%) of 73,290 cases with available genotype data reported during 2004–2013. Most cases were identified in large metropolitan areas throughout the United States. Although M. africanumis an infrequent cause of TB, most states reported >1 case of TB caused by M. africanum during the study period, which suggested that M. africanum is broadly distributed.
In this study, TB caused by M. africanum was more likely to occur in foreign-born West Africans and US-born non-Hispanic blacks and less likely in foreign-born persons originating from countries not in West Africa. These associations suggest that the epidemiology of M. africanum in the United States is driven primarily by migration of persons from West Africa. We also identified cases of M. africanum in US-born persons, primarily in non-Hispanic blacks. This finding suggests that transmission of M. africanum might occur in the United States, but the possibility of acquisition of TB during travel (e.g., to West Africa) cannot be excluded because travel history was not available in national surveillance data. In an initial report of 5 M. africanum cases in the United States, several case-patients did not report a history of travel to West Africa (34).
The low proportion of TB cases attributed to M. africanum suggests decreased transmissibility in the United States. Reasons for decreased transmission ofM. africanum are unknown but could include decreased infectiousness or decreased progression to disease compared with M. tuberculosis, as was previously reported (8).
Our findings support the observation that M. africanum is highly restricted to West Africa, where it has been estimated to cause up to 50% of all TB cases, although the reason for this restriction remains unclear (8). A recent study from Ghana reported an association between M. africanum and patient ethnicity, which suggests specificity of host−pathogen interaction could be 1 factor in limiting the spread of M. africanum to West Africa (35).
Most M. africanum TB cases were not part of genotype clusters, which suggested that transmission of M. africanum in the United States is not common. M. africanum TB cases were less likely to be associated with genotype clustering than M. tuberculosis TB cases by analyses of all cases reported in the United States and in a subanalysis of persons born in West Africa. This lower association of clustering is consistent with investigations from Ghana and The Gambia, which found M. africanum less likely to be in spoligotype-defined clusters (30,36).
After controlling for other factors, we found that TB cases in the United States caused by M. africanum and M. tuberculosis were similar regarding clinical presentation, social risk factors, and treatment outcomes. These findings are consistent with those of studies that compared treatment outcomes among cases of M. africanum and M. tuberculosis TB in West Africa, but contrast with studies describing differential associations with HIV and chest radiography findings (8,14,28,29). Unlike several reported studies, we could not compare specific chest radiographic findings for M. africanum versus M. tuberculosisbecause detailed radiographic information is not available in US surveillance data (8). Our study demonstrated similar clinical characteristics of TB caused by L5 and L6 lineages of M. africanum, which is consistent with that of a previous report (29).
Our results should be interpreted in light of the incomplete availability of genotype data. Nationwide coverage of genotyping has increased over time (37), but genotype data were not available for all culture confirmed cases. Although it is possible that our study underestimates the true burden of M. africanum, we expect that changes in system coverage do not substantially affect the main findings of the study. In addition, M. africanum and M. tuberculosis were identified by spoligotype and MIRU-VNTR, rather than by more phylogenetically robust methods, such as large-sequence polymorphism analysis. Therefore, some misclassification might have occurred, but there is no reason to assume any bias was introduced. Finally, our definition of clustered cases was based solely on identical spoligotype and 24-locus MIRU-VNTR in the same county during 2009–2013 and therefore probably overestimates the extent of transmission that might be occurring at the county level. More robust methods for identifying clustered cases rely on a narrower time interval between cases and evidence of epidemiologic links between cases (38). Even with the direction of bias toward overestimation of clustering, we found only 1 cluster.
Although the annual number of reported TB cases in the United States has decreased in the past decade, the proportion of TB contributed by foreign-born persons has increased to >60% in recent years (39). Similar to this trend, TB caused by M. africanum is highest among foreign-born persons, which is consistent with the understanding that spread of M. africanum in countries outside Africa is driven by human migration from West Africa. Given the low burden of TB caused by M. africanum in the United States, the similarity in clinical features of TB caused by M. africanum and M. tuberculosis, and the lower odds of clustered cases of M. africanum than those of M. tuberculosis, routine reporting of TB caused by M. africanum above standard reporting for general TB does not appear warranted at this time.
Dr. Sharma is an Epidemic Intelligence Service Officer at the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. His primary interests are the epidemiology and control of infectious diseases, including TB, and drug-resistant bacteria.

Acknowledgments

We thank Lauren Cowan, James Posey, Anne Marie France, Benjamin Silk, and Thomas Navin for their assistance with genotype and surveillance data and partners at state and local public health departments for data collection.
This study was supported by the Centers for Disease Control and Prevention.

References

  1. Thorel MF. Isolation of Mycobacterium africanum from monkeys. Tubercle. 1980;61:101–4 . DOIPubMed
  2. Alfredsen S, Saxegaard F. An outbreak of tuberculosis in pigs and cattle caused by Mycobacterium africanum. Vet Rec. 1992;131:51–3 .DOIPubMed
  3. de Jong BC, Hill PC, Brookes RH, Gagneux S, Jeffries DJ, Otu JK, Mycobacterium africanum elicits an attenuated T cell response to early secreted antigenic target, 6 kDa, in patients with tuberculosis and their household contacts. J Infect Dis. 2006;193:1279–86. DOIPubMed
  4. Comas I, Chakravartti J, Small PM, Galagan J, Niemann S, Kremer K, Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet. 2010;42:498–503. DOIPubMed
  5. Firdessa R, Berg S, Hailu E, Schelling E, Gumi B, Erenso G, Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia.Emerg Infect Dis. 2013;19:460–3. DOIPubMed
  6. Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, Homolka S, High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol. 2008;6:e311. DOIPubMed
  7. Vasconcellos SE, Huard RC, Niemann S, Kremer K, Santos AR, Suffys PN, Distinct genotypic profiles of the two major clades of Mycobacterium africanum. BMC Infect Dis. 2010;10:80. DOIPubMed
  8. de Jong BC, Antonio M, Gagneux S. Mycobacterium africanum: review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis. 2010;4:e744. DOIPubMed
  9. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis. 2007;7:328–37. DOIPubMed
  10. Frothingham R, Strickland PL, Bretzel G, Ramaswamy S, Musser JM, Williams DL. Phenotypic and genotypic characterization of Mycobacterium africanum isolates from West Africa. J Clin Microbiol. 1999;37:1921–6 .PubMed
  11. Niemann S, Rusch-Gerdes S, Joloba ML, Whalen CC, Guwatudde D, Ellner JJ, Mycobacterium africanum subtype II is associated with two distinct genotypes and is a major cause of human tuberculosis in Kampala, Uganda. J Clin Microbiol. 2002;40:3398–405. DOIPubMed
  12. Sola C, Rastogi N, Gutierrez MC, Vincent V, Brosch R, Parsons L. Is Mycobacterium africanum subtype II (Uganda I and Uganda II) a genetically well-defined subspecies of the Mycobacterium tuberculosis complex? J Clin Microbiol. 2003;41:1345–6, author reply 6–8. DOIPubMed
  13. Cadmus S, Palmer S, Okker M, Dale J, Gover K, Smith N, Molecular analysis of human and bovine tubercle bacilli from a local setting in Nigeria. J Clin Microbiol. 2006;44:29–34. DOIPubMed
  14. de Jong BC, Hill PC, Aiken A, Awine T, Antonio M, Adetifa IM, Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis. 2008;198:1037–43. DOIPubMed
  15. Cadmus SI, Yakubu MK, Magaji AA, Jenkins AO, van Soolingen D. Mycobacterium bovis, but also M. africanum present in raw milk of pastoral cattle in north-central Nigeria. Trop Anim Health Prod. 2010;42:1047–8. DOIPubMed
  16. Gomgnimbou MK, Refregier G, Diagbouga SP, Adama S, Kabore A, Ouiminga A, Spoligotyping of Mycobacterium africanum, Burkina Faso. Emerg Infect Dis. 2012;18:117–9. DOIPubMed
  17. Lawson L, Zhang J, Gomgnimbou MK, Abdurrahman ST, Le Moullec S, Mohamed F, A molecular epidemiological and genetic diversity study of tuberculosis in Ibadan, Nnewi and Abuja, Nigeria. PLoS ONE. 2012;7:e38409. DOIPubMed
  18. Aliyu G, El-Kamary SS, Abimiku A, Brown C, Tracy K, Hungerford L, Prevalence of non-tuberculous mycobacterial infections among tuberculosis suspects in Nigeria. PLoS ONE. 2013;8:e63170. DOIPubMed
  19. Gehre F, Antonio M, Faihun F, Odoun M, Uwizeye C, de Rijk P, The first phylogeographic population structure and analysis of transmission dynamics of M. africanum West African 1—combining molecular data from Benin, Nigeria and Sierra Leone. PLoS ONE. 2013;8:e77000. DOIPubMed
  20. Gehre F, Antonio M, Otu JK, Sallah N, Secka O, Faal T, Immunogenic Mycobacterium africanum strains associated with ongoing transmission in The Gambia. Emerg Infect Dis. 2013;19:1598–604. DOIPubMed
  21. Kuaban C, Um Boock A, Noeske J, Bekang F, Eyangoh S. Mycobacterium tuberculosis complex strains and drug susceptibility in a cattle-rearing region of Cameroon. Int J Tuberc Lung Dis. 2014;18:34–8. DOIPubMed
  22. Lari N, Rindi L, Bonanni D, Rastogi N, Sola C, Tortoli E, Three-year longitudinal study of genotypes of Mycobacterium tuberculosis isolates in Tuscany, Italy. J Clin Microbiol. 2007;45:1851–7. DOIPubMed
  23. Grange JM, Yates MD. Incidence and nature of human tuberculosis due to Mycobacterium africanum in South-East England: 1977–87. Epidemiol Infect. 1989;103:127–32. DOIPubMed
  24. Jungbluth H, Fink H, Reusch F. Tuberculous infection caused by Myco. africanum in black africans resident in the German Federal Republic (author’s transl) [in German]. Prax Klin Pneumol. 1978;32:306–9 .PubMed
  25. Isea-Peña MC, Brezmes-Valdivieso MF, Gonzalez-Velasco MC, Lezcano-Carrera MA, Lopez-Urrutia-Lorente L, Martin-Casabona N, Mycobacterium africanum, an emerging disease in high-income countries? Int J Tuberc Lung Dis. 2012;16:1400–4. DOIPubMed
  26. Gomes HM, Elias AR, Oelemann MA, Pereira MA, Montes FF, Marsico AG, Spoligotypes of Mycobacterium tuberculosis complex isolates from patients residents of 11 states of Brazil. Infect Genet Evol. 2012;12:649–56 . DOIPubMed
  27. Desmond E, Ahmed AT, Probert WS, Ely J, Jang Y, Sanders CA, Mycobacterium africanum cases, California. Emerg Infect Dis. 2004;10:921–3.DOIPubMed
  28. de Jong BC, Adetifa I, Walther B, Hill PC, Antonio M, Ota M, Differences between TB cases infected with M. africanum, West-African type 2, relative to Euro-American M. tuberculosis: an update. FEMS Immunol Med Microbiol. 2010;58:102–5. DOIPubMed
  29. Meyer CG, Scarisbrick G, Niemann S, Browne EN, Chinbuah MA, Gyapong J, Pulmonary tuberculosis: virulence of Mycobacterium africanum and relevance in HIV co-infection. Tuberculosis (Edinb). 2008;88:482–9. DOIPubMed
  30. de Jong BC, Hill PC, Aiken A, Jeffries DJ, Onipede A, Small PM, Clinical presentation and outcome of tuberculosis patients infected by M. africanumversus M. tuberculosis. Int J Tuberc Lung Dis. 2007;11:450–6 .PubMed
  31. Moonan PK, Ghosh S, Oeltmann JE, Kammerer JS, Cowan LS, Navin TR. Using genotyping and geospatial scanning to estimate recent Mycobacterium tuberculosis transmission, United States. Emerg Infect Dis. 2012;18:458–65. DOIPubMed
  32. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2012. Atlanta: The Centers; 2013.
  33. Click ES, Moonan PK, Winston CA, Cowan LS, Oeltmann JE. Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. Clin Infect Dis. 2012;54:211–9. DOIPubMed
  34. Desmond E, Ahmed AT, Probert WS, Ely J, Jang Y, Sanders CA, Mycobacterium africanum cases, California. Emerg Infect Dis. 2004;10:921–3.DOIPubMed
  35. Asante-Poku A, Yeboah-Manu D, Otchere ID, Aboagye SY, Stucki D, Hattendorf J, Mycobacterium africanum is associated with patient ethnicity in Ghana. PLoS Negl Trop Dis. 2015;9:e3370 and. DOIPubMed
  36. Yeboah-Manu D, Asante-Poku A, Bodmer T, Stucki D, Koram K, Bonsu F, Genotypic diversity and drug susceptibility patterns among M. tuberculosiscomplex isolates from southwestern Ghana. PLoS ONE. 2011;6:e21906. DOIPubMed
  37. Centers for Disease Control and Prevention. Tuberculosis genotyping—United States, 2004–2010. MMWR Morb Mortal Wkly Rep. 2012;61:723–5.PubMed
  38. Moonan PK, Ghosh S, Oeltmann JE, Kammerer JS, Cowan LS, Navin TR. Using genotyping and geospatial scanning to estimate recent Mycobacterium tuberculosis transmission, United States. Emerg Infect Dis. 2012;18:458–65. DOIPubMed
  39. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2013: Atlanta: The Centers.

Figures

Table

Technical Appendix

Suggested citation for this article: Sharma A, Bloss E, Heilig CM, Click ES. Tuberculosis caused by Mycobacterium africanum, United States, 2004–2013. Emerg Infect Dis. 2016 Mar [date cited]. http://dx.doi.org/10.3201/eid2203.151505
DOI: 10.3201/eid2203.151505


Related Links

Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)